Search

Your search keyword '"Mourits-Andersen, Hans Torben"' showing total 6 results
Start Over Author "Mourits-Andersen, Hans Torben" Database OpenAIRE
6 results on '"Mourits-Andersen, Hans Torben"'

1. IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL

Author

Andersen Patel, Dustin, Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lucas Frans, Weiss Bjerrum, Ole, Brabrand, Mette, Ellervik, Christina, el Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Lindholm Sørensen, Anders, Jesper, Stentoft, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2019

2. Long-term Efficacy and Safety of Recombinant Interferon Alpha-2 vs. Hydroxyurea in Polycythemia Vera: Preliminary Results From the Three-Year Analysis of the DALIAH Trial – A Randomized Controlled Phase III Clinical Trial

Author

Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lukas Frans, Weiss Bjerrum, Ole, Brabrand, Mette, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2018

3. Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients

Author

Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lukas Frans, Weiss Bjerrum, Ole, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe Henriette, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2018

4. Interim analysis of the Daliah trial - a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients

Author

Knudsen, Trine Alma, Lund Hansen, Dennis, Ocias, Lukas Frans, Weiss Bjerrum, Ole, Brabrand, Mette, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kielsgaard Kristensen, Thomas, Kruse, Torben A, Mourits-Andersen, Hans Torben, Møller, Peter, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe Henriette, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas Stauffer, and Hasselbalch, Hans Carl

Published
2018
Full Text
View/download PDF

5. Safety And Efficacy Of Combination Therapy Of Interferon Αlpha-2 And Ruxolitinib In Polycythemia Vera And Low-/Intermediate-1-Risk Myelofibrosis – A One Year Follow-Up Update Of A Phase II Study

Author

Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Skov, Vibe, Andersen, Christen Bertel Lykkegaard, Weiss Bjerrum, Ole, Brochmann Mortensen, Nana, El Fassi, Daniel, Kruse, Torben A, Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, and Hasselbalch, Hans Carl

Published
2018

6. Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier

Author

Ocias, Lukas Frans, Holmström, Morten Orebo, Riley, Caroline Hasselbalch, Andersen, Christen Lykkegaard, Rønnov-Jessen, Dorthe, Starklint, Jørn, Frederiksen, Mikael, Steffensen, Morten Saabye, Bjerrum, Ole Weis, Farmer, Sarah, Mourits-Andersen, Hans Torben, Hasselbalch, Hans Carl, and Larsen, Thomas Stauffer

Subjects
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Myeloproliferative Disorders/drug therapy, Polycythemia Vera/drug therapy, hemic and lymphatic diseases, Janus Kinase 2/antagonists & inhibitors, Humans, Interferon-alpha/therapeutic use, Thrombocytosis/drug therapy, Algorithms, Primary Myelofibrosis/drug therapy
Abstract

Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results